NovaBay Pharmaceuticals, Inc.
NBY
$0.58
-$0.02-3.33%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 11.15M | 11.20M | 12.33M | 12.04M | 11.96M |
| Total Other Revenue | 48.00K | 41.00K | 39.00K | 39.00K | 40.00K |
| Total Revenue | 11.20M | 11.24M | 12.37M | 12.08M | 12.00M |
| Cost of Revenue | 4.41M | 4.38M | 5.36M | 5.27M | 5.24M |
| Gross Profit | 6.79M | 6.86M | 7.01M | 6.82M | 6.76M |
| SG&A Expenses | 11.24M | 10.95M | 11.08M | 10.67M | 12.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.68M | 15.36M | 16.49M | 15.97M | 17.78M |
| Operating Income | -4.48M | -4.12M | -4.12M | -3.89M | -5.78M |
| Income Before Tax | -10.00M | -10.14M | -10.28M | -8.53M | -12.63M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.00 | -10.14 | -10.28 | -8.53 | -12.63 |
| Earnings from Discontinued Operations | -124.00K | -528.00K | -836.00K | -1.11M | -1.11M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.12M | -10.66M | -11.12M | -9.64M | -13.74M |
| EBIT | -4.48M | -4.12M | -4.12M | -3.89M | -5.78M |
| EBITDA | -4.40M | -4.03M | -4.03M | -3.80M | -5.62M |
| EPS Basic | -53.60 | -66.11 | -109.05 | -133.86 | -239.05 |
| Normalized Basic EPS | -7.98 | -14.09 | -25.42 | -37.84 | -53.84 |
| EPS Diluted | -53.60 | -66.11 | -109.05 | -133.86 | -239.05 |
| Normalized Diluted EPS | -7.98 | -14.09 | -25.42 | -37.84 | -53.84 |
| Average Basic Shares Outstanding | 5.77M | 2.19M | 1.13M | 480.20K | 337.20K |
| Average Diluted Shares Outstanding | 5.77M | 2.19M | 1.13M | 480.20K | 337.20K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
